Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53

被引:40
作者
Chipoy, C.
Brounais, B.
Trichet, V.
Battaglia, S.
Berreur, M.
Oliver, L.
Juin, P.
Redini, F.
Heymann, D.
Blanchard, F.
机构
[1] Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F-44035 Nantes 1, France
[2] INSERM, ER17, Nantes, France
[3] INSERM, U601, Nantes, France
关键词
osteosarcoma; osteoblast; oncostatin M; STAT5; p53; apoptosis;
D O I
10.1038/sj.onc.1210492
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oncostatin M ( OSM), a cytokine of the interleukin- 6 family, induces growth arrest and differentiation of osteoblastic cells into glial- like/ osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed ( osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-alpha. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases- 9 and - 3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl- 2 and Mcl- 1. Pharmacological inhibitors, dominant- negative signal transducer and activator of transcriptions ( STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl- 2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating ( i) activation and nuclear translocation of STAT5 and p53 and ( ii) an increased Bax/ Bcl- 2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild- type p53 osteosarcoma.
引用
收藏
页码:6653 / 6664
页数:12
相关论文
共 38 条
[1]   The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells [J].
Auernhammer, CJ ;
Dorn, F ;
Vlotides, G ;
Hengge, S ;
Kopp, FB ;
Spoettl, G ;
Cengic, N ;
Engelhardt, D ;
Weber, MM .
JOURNAL OF ENDOCRINOLOGY, 2004, 180 (03) :479-486
[2]   Signaling of type II oncostatin M receptor [J].
Auguste, P ;
Guillet, C ;
Fourcin, M ;
Olivier, C ;
Veziers, J ;
PouplardBarthelaix, A ;
Gascan, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (25) :15760-15764
[3]  
Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
[4]   Endotoxin-induced renal inflammatory response - Oncostatin M as a major mediator of suppressed renin expression [J].
Baumann, H ;
Wang, YP ;
Richards, CD ;
Jones, CA ;
Black, TA ;
Gross, KW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (29) :22014-22019
[5]   Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation [J].
Bellido, T ;
Borba, VZC ;
Roberson, P ;
Manolagas, SC .
ENDOCRINOLOGY, 1997, 138 (09) :3666-3676
[6]  
Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1
[7]   Signal transducer and activator of transcription 5 (STAT5) [J].
Buitenhuis, M ;
Coffer, PJ ;
Koenderman, L .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (11) :2120-2124
[8]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[9]  
CASEY G, 1991, ONCOGENE, V6, P1791
[10]   INACTIVATION OF P53 GENE IN HUMAN AND MURINE OSTEOSARCOMA CELLS [J].
CHANDAR, N ;
BILLIG, B ;
MCMASTER, J ;
NOVAK, J .
BRITISH JOURNAL OF CANCER, 1992, 65 (02) :208-214